Recursion Pharmaceuticals (RXRX) said Wednesday that it has completed its business combination with Exscientia (EXAI) and Exscientia is now a wholly owned unit of Recursion.
Exscientia's American depositary shares have stopped trading and will be delisted from Nasdaq, according to Recursion.
The combined company has received about $450 million in upfront and milestone payments from partners and has more than 10 partnered programs in areas such as oncology and immunology, Recursion added.
The deal was first announced in August.